Novo Nordisk A/S (LON: 0TDD)

Market Cap	292.68B
Revenue (ttm)	30.19B
Net Income (ttm)	10.57B
Shares Out	n/a
EPS (ttm)	2.37
PE Ratio	27.69
Forward PE	n/a
Dividend	0.81 (1.03%)
Ex-Dividend Date	Aug 16, 2024

Volume	16,509
Average Volume	43,326
Open	80.99
Previous Close	80.93
Day's Range	80.84 - 82.50
52-Week Range	98.88 - 149.80
Beta	n/a
RSI	34.58
Earnings Date	Feb 5, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 64,319
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0TDD

Financial Performance

In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.

Financial numbers in DKK